188 related articles for article (PubMed ID: 19780707)
1. Targeting of HDAC8 and investigational inhibitors in neuroblastoma.
Oehme I; Deubzer HE; Lodrini M; Milde T; Witt O
Expert Opin Investig Drugs; 2009 Nov; 18(11):1605-17. PubMed ID: 19780707
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
[TBL] [Abstract][Full Text] [Related]
3. HDAC family: What are the cancer relevant targets?
Witt O; Deubzer HE; Milde T; Oehme I
Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Rettig I; Koeneke E; Trippel F; Mueller WC; Burhenne J; Kopp-Schneider A; Fabian J; Schober A; Fernekorn U; von Deimling A; Deubzer HE; Milde T; Witt O; Oehme I
Cell Death Dis; 2015 Feb; 6(2):e1657. PubMed ID: 25695609
[TBL] [Abstract][Full Text] [Related]
5. Cloning and characterization of a novel human histone deacetylase, HDAC8.
Buggy JJ; Sideris ML; Mak P; Lorimer DD; McIntosh B; Clark JM
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):199-205. PubMed ID: 10926844
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
7. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
9. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
Suzuki T; Ota Y; Ri M; Bando M; Gotoh A; Itoh Y; Tsumoto H; Tatum PR; Mizukami T; Nakagawa H; Iida S; Ueda R; Shirahige K; Miyata N
J Med Chem; 2012 Nov; 55(22):9562-75. PubMed ID: 23116147
[TBL] [Abstract][Full Text] [Related]
10. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
11. Targeting class I histone deacetylases in cancer therapy.
Delcuve GP; Khan DH; Davie JR
Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
[TBL] [Abstract][Full Text] [Related]
12. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Waltregny D; North B; Van Mellaert F; de Leval J; Verdin E; Castronovo V
Eur J Histochem; 2004; 48(3):273-90. PubMed ID: 15590418
[TBL] [Abstract][Full Text] [Related]
13. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
de Ruijter AJ; Kemp S; Kramer G; Meinsma RJ; Kaufmann JO; Caron HN; van Kuilenburg AB
Biochem Pharmacol; 2004 Oct; 68(7):1279-88. PubMed ID: 15345317
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
15. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
17. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Lopez G; Pollock RE
Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
[TBL] [Abstract][Full Text] [Related]
19. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
20. Expression profile of class I histone deacetylases in human cancer tissues.
Nakagawa M; Oda Y; Eguchi T; Aishima S; Yao T; Hosoi F; Basaki Y; Ono M; Kuwano M; Tanaka M; Tsuneyoshi M
Oncol Rep; 2007 Oct; 18(4):769-74. PubMed ID: 17786334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]